The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Adalimumab + Methotrexate Effective for Uveitis in JIA

Adalimumab + Methotrexate Effective for Uveitis in JIA

October 2, 2017 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Researchers have peppered the medical literature with an increasing number of clinical trials designed to test the efficacy and safety of treatments for uveitis, a collection of ocular diseases characterized by intraocular inflammation. Unfortunately, few of these trials have targeted childhood uveitis, which can cause blindness. This past spring, researchers published some much-needed good news: the results of the SYCAMORE trial of adalimumab in children with juvenile idiopathic arthritis (JIA)-associated uveitis. The trial revealed that children and adolescents with active JIA-associated uveitis who were taking a stable dose of methotrexate had reduced inflammation and a lower rate of treatment failure if they also received adalimumab.

You Might Also Like
  • Health Canada Approves Adalimumab for Chronic Non-Infectious Anterior Uveitis in Pediatric Patients
  • Aggressive Treatment of Inflammation Prevents Vision Loss in Patients with JIA-related Uveitis
  • Treating Uveitis with Adalimumab Improves Quality of Life
Also By This Author
  • Gene Signatures in IgG4-Related Disease

Athimalaipet V. Ramanan, FRCPCH, FRCP, professor of pediatric rheumatology at the University of Bristol in the U.K., and colleagues also found that patients who received adalimumab had a much higher incidence of adverse and serious adverse events than those who received methotrexate plus placebo. They published the results of their randomized, placebo-controlled trial in the April 27 issue of the New England Journal of Medicine.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The study’s primary endpoint was treatment failure based on a multi-component intraocular inflammation score. This score included the anterior chamber cell count, which is known as the standardization of uveitis (SUN) criteria. The investigators acknowledge in their paper that the SUN criteria are not currently validated in children.

The team found that treatment with adalimumab significantly delayed the time to treatment failure relative to treatment with methotrexate alone (hazard ratio, 0.25; 95% CI, 0.12 to 0.49; P<0.0001). In fact, the researchers terminated the trial early because of this strong beneficial effect of adalimumab treatment. This prespecified stopping criterion was met after 90 of 114 patients were enrolled in the trial. All told, the investigators documented a 27% treatment failure rate in adalimumab-treated patients and a 60% treatment failure rate in methotrexate-plus-placebo-treated patients. Unfortunately, patients treated with adalimumab also experienced more adverse events, such as minor infections, respiratory disorders and gastrointestinal disorders, than patients treated with methotrexate plus placebo.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Methotrexate Treatment
In an accompanying editorial, Jennifer E. Thorne, MD, PhD, professor of ophthalmology at Johns Hopkins University School of Medicine in Baltimore, notes that because the trial was performed in children who had active disease despite methotrexate treatment, it’s likely the results cannot be generalized to all patients being treated for JIA-associated uveitis.2

The role of methotrexate in the outcomes was further discussed in later correspondence with the editor. A letter by Shiqiao Peng, PhD, and colleagues at the First Affiliated Hospital of China Medical University in Shenyang notes that children received methotrexate either orally or via subcutaneous injection, a difference that may have affected outcomes in the study.3

Pages: 1 2 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: adalimumab, JIA, Juvenile Arthritis (JIA), metho­trexate, Pediatric, Pediatric Rheumatology, Uveitis

You Might Also Like:
  • Health Canada Approves Adalimumab for Chronic Non-Infectious Anterior Uveitis in Pediatric Patients
  • Aggressive Treatment of Inflammation Prevents Vision Loss in Patients with JIA-related Uveitis
  • Treating Uveitis with Adalimumab Improves Quality of Life
  • Rituximab May Benefit Patients with Refractory JIA-Associated Uveitis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)